1
|
Xia HB, Zhu XD, Zhu Y, Xu AM. Comprehensive analysis of the prognostic and immunological roles of TIPE3 in Colon Cancer. Asian J Surg 2024; 47:1530-1532. [PMID: 38071098 DOI: 10.1016/j.asjsur.2023.11.162] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/30/2023] [Accepted: 11/24/2023] [Indexed: 03/13/2024] Open
Affiliation(s)
- Heng-Bo Xia
- Department of General Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei, 230032, China
| | - Xiao-Dong Zhu
- Department of General Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei, 230032, China
| | - Yong Zhu
- Department of General Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei, 230032, China.
| | - A-Man Xu
- Department of General Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei, 230032, China; Anhui Public Health Clinical Center, Hefei, 230032, China.
| |
Collapse
|
2
|
Panda AK, Tripathy R, Das BK. CD14 (C-159T) polymorphism is associated with increased susceptibility to SLE, and plasma levels of soluble CD14 is a novel biomarker of disease activity: A hospital-based case-control study. Lupus 2020; 30:219-227. [PMID: 33176568 DOI: 10.1177/0961203320972799] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
BACKGROUND Cluster of differentiation 14 (CD14) plays a crucial role in the innate immune response of the host in protection against various pathogens. The importance of soluble CD14 in autoimmune disorders has been described in different populations. However, the role of sCD14 in systemic lupus erythematosus (SLE) is poorly understood. Further, the association of functional variants at the promoter region of the CD14 gene (-159 C > T) with susceptibility to SLE or disease severity needs to be defined. METHODS Two hundred female SLE patients diagnosed on systemic lupus international collaborating clinics (SLICC) classification criteria and age, sex, matched healthy controls were enrolled in the present study. Polymerase chain reaction- restriction fragment length polymorphism (PCR-RFLP) method was used to genotype CD14 (C-159 T) polymorphism. Plasma levels of IFN-α, TNF-α, and sCD14 were quantified by enzyme-linked immunosorbent assay (ELISA). RESULTS Prevalence of mutant genotypes (CT and TT) and minor allele (T) of CD14 (C-159T) polymorphism was significantly higher in SLE cases compared to healthy controls (CT: P < 0.0001; OR = 3.26, TT:P < 0.0001; OR = 3.39; T:P = 0.0009, OR = 1.62). Further, lupus nephritis patients had a higher prevalence of homozygous mutants (TT) and mutant allele (T)(TT: P = 0.0002, OR = 8.07; T: P = 0.001, OR = 1.32). SLE patients displayed significantly increased plasma sCD14, TNF-α, and IFN-α levels in comparison to healthy controls. These cytokines were significantly elevated in patients of lupus nephritis compared to those without kidney involvement. Interestingly, sCD14 levels correlated positively with SLE disease activity index-2K (SLEDAI-2K) scores and 24 hours proteinuria. CONCLUSION CD14 (C-159T) polymorphism is associated with an increased predisposition to the development of SLE and lupus nephritis: sCD14 is a promising novel biomarker for assessing disease activity and lupus nephritis.
Collapse
Affiliation(s)
- Aditya K Panda
- Department of Bioscience and Bioinformatics, Khallikote University, Berhampur, India
| | - Rina Tripathy
- Department of Biochemistry, SVP Post-Graduate Institute of Pediatrics, Cuttack, Odisha, India
| | - Bidyut K Das
- Department of Medicine, S.C.B. Medical College, Cuttack, India
| |
Collapse
|
3
|
Venkataraman I, Naides SJ. The Development of New Diagnostic Tests for Neurologic Disorders in the Commercial Laboratory Environment. Clin Lab Med 2020; 40:331-339. [PMID: 32718503 DOI: 10.1016/j.cll.2020.06.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
Development of new diagnostic tests in a commercial laboratory for neurologic disorders is challenging. Development occurs in a highly regulated environment. Relevant research infrastructure may not be readily available in-house and may require outsourcing with additional management and costs. Clinically characterized specimens for validation of biomarkers for esoteric diseases may be difficult to acquire, and market size may be difficult to predict. More common diseases with heterogeneous subsets may require better clinical definition. Absence of guidelines may delay health provider acceptance of novel testing. Regulatory agency approval and categorization of tests affects validation requirements and impacts market acceptance and reimbursement.
Collapse
Affiliation(s)
- Iswariya Venkataraman
- Scientific Affairs, EUROIMMUN US, 1 Bloomfield Avenue, Mountain Lakes, New Jersey 07046, USA
| | - Stanley J Naides
- Scientific Affairs, EUROIMMUN US, 1 Bloomfield Avenue, Mountain Lakes, New Jersey 07046, USA.
| |
Collapse
|
4
|
Wang, DC, Wang, W, Zhu, B, Wang X. Lung Cancer Heterogeneity and New Strategies for Drug Therapy. Annu Rev Pharmacol Toxicol 2018; 58:531-546. [PMID: 28977762 DOI: 10.1146/annurev-pharmtox-010716-104523] [Citation(s) in RCA: 44] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- Diane C. Wang,
- Zhongshan Hospital Institute of Clinical Science, Shanghai Institute of Clinical Bioinformatics, Fudan University Center for Clinical Bioinformatics, Shanghai 200032, China
| | - William Wang,
- Zhongshan Hospital Institute of Clinical Science, Shanghai Institute of Clinical Bioinformatics, Fudan University Center for Clinical Bioinformatics, Shanghai 200032, China
| | - Bijun Zhu,
- Zhongshan Hospital Institute of Clinical Science, Shanghai Institute of Clinical Bioinformatics, Fudan University Center for Clinical Bioinformatics, Shanghai 200032, China
| | - Xiangdong Wang
- Zhongshan Hospital Institute of Clinical Science, Shanghai Institute of Clinical Bioinformatics, Fudan University Center for Clinical Bioinformatics, Shanghai 200032, China
| |
Collapse
|
5
|
Abstract
The precision medicine as a new emerging area and therapeutic strategy has occurred and was practiced in the individual and brought unexpected successes, and gained high attentions from professional and social aspects as a new path to improve the treatment and prognosis of patients. There will be a number of new components to appear or be discovered, of which clinical bioinformatics integrates clinical phenotypes and informatics with bioinformatics, computational science, mathematics, and systems biology. In addition to those tools, precision medicine calls more accurate and repeatable methodologies for the identification and validation of gene discovery. Precision medicine will bring more new therapeutic strategies, drug discovery and development, and gene-oriented treatment. There is an urgent need to identify and validate disease-specific, mechanism-based, or epigenetics-dependent biomarkers to monitor precision medicine, and develop "precision" regulations to guard the application of precision medicine.
Collapse
Affiliation(s)
- Chengshui Chen
- Department of Respiratory Medicine, Wenzhou Medical University affiliated The First Hospital, Wenzhou, China
| | | | | | | | | |
Collapse
|
6
|
Chen YL, Chen CH, Wallace CG, Wang HT, Yang CC, Yip HK. Levels of circulating microparticles in patients with chronic cardiorenal disease. J Atheroscler Thromb 2014; 22:247-56. [PMID: 25342381 DOI: 10.5551/jat.26658] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023] Open
Abstract
AIM Cardiac and renal diseases are common disorders that frequently coexist. We tested the hypothesis that the levels of circulating endothelial-derived apoptotic microparticles (EDA-MPs; CD31(+)CD42b(-)AN(-)V(+)) and platelet-derived apoptotic microparticles (PDA-MPs; CD31(+)CD42b(+)AN(-)V(+)) are useful biomarkers for predicting the presence of cardiorenal disease (CRD). METHODS A total of 68 patients with chronic kidney disease (CKD) and angina pectoris (CKD-AP) undergoing cardiac catheterization were prospectively enrolled into group 1, 10 patients with coronary artery disease (CAD) without CKD were enrolled into group 2 (CAD(+)CKD(-)) and 10 patients without CAD and CKD were enrolled into group 3 (CAD(-)CKD(-)). RESULTS The serum creatinine levels were significantly higher, whereas the estimated glomerular filtration rates (eGFRs) were significantly lower, in group 1 than in the other two groups (all p < 0.02). The circulating levels of EDA-MPs and PDA-MPs did not differ between the patients with and without CKD (all p > 0.2). However, the circulating levels of EDA-MPs and PDA-MPs were significantly higher in group 2 than in groups 1 and 3 (all p < 0.03). In addition, differences were noted in the circulating EDA-MP and PDA-MP levels between groups 1 and 3, although without statistical significance (all p > 0.09). Meanwhile, among the CKD patients, the subgroup analysis showed that the levels of MPs were significantly higher in those with CAD than in those without (all p=0.001), while a multivariate analysis demonstrated that CAD was the only factor independently predictive of high levels of circulating EDA-MPs and PDA-MPs (p=0.033). CONCLUSIONS The link with increased circulating levels of MPs is more consistent in patients with CAD than in those with CKD.
Collapse
Affiliation(s)
- Yung-Lung Chen
- Division of cardiology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine
| | | | | | | | | | | |
Collapse
|
7
|
Wang X, Ward PA. Retraction Note: Opportunities and challenges of disease biomarkers: a new section in the journal of translational medicine. Lab Invest 2013; 11:144. [PMID: 23758750 PMCID: PMC3680212 DOI: 10.1186/1479-5876-11-144] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/06/2013] [Accepted: 06/06/2013] [Indexed: 11/10/2022]
|
8
|
Wang X, Peer D, Petersen B. Molecular and Cellular Therapies: New challenges and opportunities. MOLECULAR AND CELLULAR THERAPIES 2013; 1:1. [PMID: 26056567 PMCID: PMC4448952] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Received: 07/25/2013] [Accepted: 07/25/2013] [Indexed: 11/21/2023]
Abstract
Gene therapy is suggested to be one of the most specific and efficient modulations for gene deficient diseases and extended to other diseases like cancer and inflammation, even though there are still challenges to be faced, such as specific and selective delivery, minimal to no toxicity, efficient metabolism, simplicity, and measurable efficiency. It is important to identify and validate drug-able disease-specific targets for molecular and cellular therapies, while it is equally important to have disease biomarkers to trace and define the biological effects of molecular and cellular therapies. The importance and significance of allostery in molecular and cellular therapies and "allosteric disease", "allosteric effect", and "allosteric drug" should be more carefully examined and validated. Cell therapy has been attracting an increasing amount of consideration in the development of new treatments for diseases. Molecular and Cellular Therapies (MCT) is a new, open-access journal, devoted to molecular mechanisms, preclinical and clinical research and development of gene-, peptide-, protein-, and cell-based therapies.
Collapse
Affiliation(s)
- Xiangdong Wang
- />Shanghai Institute of Respiratory Diseases; Department of Respiratory Medicine, Fudan University Zhongshan Hospital, Shanghai, Sweden
- />Institute of Clinical Science, Lund University, Lund, Sweden
| | - Dan Peer
- />Department of Cell Research & Immunology, Laboratory of NanoMedicine, and the center for Nanoscience and Nanotechnology, Tel Aviv University, Tel Aviv, Israel
| | - Bryon Petersen
- />Department of Pediatrics, University of Florida, Children Health Research Institute, Gainesville, FL USA
| |
Collapse
|
9
|
Wang X, Peer D, Petersen B. Molecular and Cellular Therapies: New challenges and opportunities. MOLECULAR AND CELLULAR THERAPIES 2013; 1:1. [PMID: 26056567 PMCID: PMC4448952 DOI: 10.1186/2052-8426-1-1] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Received: 07/25/2013] [Accepted: 07/25/2013] [Indexed: 12/21/2022]
Abstract
Gene therapy is suggested to be one of the most specific and efficient modulations for gene deficient diseases and extended to other diseases like cancer and inflammation, even though there are still challenges to be faced, such as specific and selective delivery, minimal to no toxicity, efficient metabolism, simplicity, and measurable efficiency. It is important to identify and validate drug-able disease-specific targets for molecular and cellular therapies, while it is equally important to have disease biomarkers to trace and define the biological effects of molecular and cellular therapies. The importance and significance of allostery in molecular and cellular therapies and "allosteric disease", "allosteric effect", and "allosteric drug" should be more carefully examined and validated. Cell therapy has been attracting an increasing amount of consideration in the development of new treatments for diseases. Molecular and Cellular Therapies (MCT) is a new, open-access journal, devoted to molecular mechanisms, preclinical and clinical research and development of gene-, peptide-, protein-, and cell-based therapies.
Collapse
Affiliation(s)
- Xiangdong Wang
- Shanghai Institute of Respiratory Diseases; Department of Respiratory Medicine, Fudan University Zhongshan Hospital, Shanghai, Sweden ; Institute of Clinical Science, Lund University, Lund, Sweden
| | - Dan Peer
- Department of Cell Research & Immunology, Laboratory of NanoMedicine, and the center for Nanoscience and Nanotechnology, Tel Aviv University, Tel Aviv, Israel
| | - Bryon Petersen
- Department of Pediatrics, University of Florida, Children Health Research Institute, Gainesville, FL USA
| |
Collapse
|
10
|
Sasseville VG, Mansfield KG, Brees DJ. Safety biomarkers in preclinical development: translational potential. Vet Pathol 2013; 51:281-91. [PMID: 24091814 DOI: 10.1177/0300985813505117] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
Abstract
The identification, application, and qualification of safety biomarkers are becoming increasingly critical to successful drug discovery and development as companies are striving to develop drugs for difficult targets and for novel disease indications in a risk-adverse environment. Translational safety biomarkers that are minimally invasive and monitor drug-induced toxicity during human clinical trials are urgently needed to assess whether toxicities observed in preclinical toxicology studies are relevant to humans at therapeutic doses. The interpretation of data during the biomarker qualification phase should include careful consideration of the analytic method used, the biology, pharmacokinetic and pharmacodynamic properties of the biomarker, and the pathophysiology of the process studied. The purpose of this review is to summarize commonly employed technologies in the development of fluid- and tissue-based safety biomarkers in drug discovery and development and to highlight areas of ongoing novel assay development.
Collapse
Affiliation(s)
- V G Sasseville
- Discovery and Investigative Safety, Preclinical Safety, Novartis Institutes for Biomedical Research, Cambridge, MA 02139, USA.
| | | | | |
Collapse
|